Key result
Prediabetes was associated with a higher risk of all-cause death compared to normoglycemia (aHR 1.483; 95% CI 1.027-2.143; P=0.036) in patients with STEMI and multivessel disease.
Why the study?
The study was conducted to evaluate the clinical implications of prediabetes compared with diabetes on 2-year major clinical outcomes in patients with STEMI and multivessel disease who received drug-eluting stents.
Does prediabetes have a similar impact as diabetes on 2-year major clinical outcomes in patients with STEMI and multivessel disease undergoing PCI compared to normoglycemia?
Cohort (n=4,097)
Does prediabetes have a similar impact as diabetes on 2-year major clinical outcomes in patients with STEMI and multivessel disease undergoing PCI compared to normoglycemia?
Hazard Ratio: 1.483 (95% CI 1.027–2.143)
p-value: p=.036
Prediabetes has a similar negative prognostic impact as established diabetes on 2-year clinical outcomes in patients with STEMI and multivessel disease undergoing PCI.
No takes yet. Share an insight, caveat, or question.
Prediabetes warrants vigilance in post-STEMI risk assessment; leaves open whether glycemic intervention improves outcomes in multivessel disease.
Kim et al. (2020) conducted a cohort in STEMI and multivessel disease (n=4,097). Prediabetes vs. Normoglycemia was evaluated on All-cause death (aHR 1.483, 95% CI 1.027-2.143, p=.036). Prediabetes was associated with a higher risk of all-cause death compared to normoglycemia (aHR 1.483; 95% CI 1.027-2.143; P=0.036) in patients with STEMI and multivessel disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: